What does Ocular Therapeutix’s positive pre-NDA meeting mean for AXPAXLI approval?
Ocular Therapeutix keeps its AXPAXLI wet AMD NDA on track for Q4 after a positive FDA meeting, but OCUL still falls nearly 5%.
Pharma & Biotech